|Articles|March 31, 2023

Recommendations for Accelerating Cell and Gene Therapies

Author(s)Cognizant

While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.


Related to this article

Pharmaceutical executive daily
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.